Patents by Inventor Xinzhen SHI

Xinzhen SHI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CONJUGATE OF ANTIBODY-ERIBULIN OR DERIVATIVE THEREOF, INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF
    Publication number: 20250144229
    Abstract: A conjugate of antibody-eribulin or a derivative thereof, an intermediate thereof, a preparation method therefor, a pharmaceutical composition thereof and use thereof. The conjugate of the antibody-eribulin or the derivative thereof provided herein as shown in general formula I is shown below. The conjugate of general formula I has high anti-tumor activity and high stability in circulation, and has excellent tumor tissue targeting property and therapeutic indexes.
    Type: Application
    Filed: February 15, 2023
    Publication date: May 8, 2025
    Inventors: Tongtong XUE, Liang XIAO, Shuai SONG, Xinzhen SHI, Jundong LI, Jiaqiang CAI
  • Interleukin-2 and use thereof
    Patent number: 12269855
    Abstract: The present invention relates to a novel interleukin-2 (IL-2) mutant protein and use thereof. In particular, the present invention relates to an IL-2 mutant protein with reduced IL-2R? receptor binding ability and/or increased IL-2R? receptor binding ability compared with the wild-type IL-2. The present invention further provides a fusion protein and an immunoconjugate comprising the IL-2 mutant protein, a nucleic acid encoding the IL-2 mutant protein, and a vector and a host cell comprising the nucleic acid. The present invention further provides a method for preparing the IL-2 mutant protein, a pharmaceutical composition comprising the IL-2 mutant protein, and therapeutic use of the mutant protein.
    Type: Grant
    Filed: September 20, 2019
    Date of Patent: April 8, 2025
    Assignee: INNOVENT BIOLOGICS (SUZHOU) CO., LTD.
    Inventors: Lishan Kang, Chunyin Gu, Fenggen Fu, Shuaixiang Zhou, Xinzhen Shi, Junjian Liu
  • Anti-TIGIT antibody and use thereof
    Patent number: 11370837
    Abstract: The present invention relates to a novel antibody and an antibody fragment thereof that specifically bind to TIGIT and a composition comprising the antibody or the antibody fragment. In addition, the present invention relates to a nucleic acid encoding the antibody or the antibody fragment thereof, a host cell comprising the nucleic acid, and related use. Furthermore, the present invention relates to therapeutic and diagnostic use of the antibody and the antibody fragment.
    Type: Grant
    Filed: July 25, 2019
    Date of Patent: June 28, 2022
    Assignee: INNOVENT BIOLOGICS (SUZHOU) CO., LTD.
    Inventors: Xinzhen Shi, Pan Zhang, Junjian Liu
  • NOVEL INTERLEUKIN-2 AND USE THEREOF
    Publication number: 20210221863
    Abstract: The present invention relates to a novel interleukin-2 (IL-2) mutant protein and use thereof. In particular, the present invention relates to an IL-2 mutant protein with reduced IL-2R? receptor binding ability and/or increased IL-2R? receptor binding ability compared with the wild-type IL-2. The present invention further provides a fusion protein and an immunoconjugate comprising the IL-2 mutant protein, a nucleic acid encoding the IL-2 mutant protein, and a vector and a host cell comprising the nucleic acid. The present invention further provides a method for preparing the IL-2 mutant protein, a pharmaceutical composition comprising the IL-2 mutant protein, and therapeutic use of the mutant protein.
    Type: Application
    Filed: September 20, 2019
    Publication date: July 22, 2021
    Inventors: Lishan KANG, Chunyin GU, Fenggen FU, Shuaixiang ZHOU, Xinzhen SHI, Junjian LIU
  • NOVEL INTERLEUKIN-2 AND USE THEREOF
    Publication number: 20210213102
    Abstract: The present invention relates to a novel interleukin-2 (IL-2) mutant protein. The present invention further provides a fusion protein and an immunoconjugate comprising the IL-2 mutant protein, a nucleic acid encoding the IL-2 mutant protein, and a vector and a host cell comprising the nucleic acid. The present invention further provides a method for preparing the IL-2 mutant protein, a pharmaceutical composition comprising the IL-2 mutant protein, and therapeutic use of the mutant protein.
    Type: Application
    Filed: September 20, 2019
    Publication date: July 15, 2021
    Inventors: Lishan KANG, Fenggen FU, Shuaixiang ZHOU, Xinzhen SHI, Junjian LIU
  • ANTI-TIGIT ANTIBODY AND USE THEREOF
    Publication number: 20210040201
    Abstract: The present invention relates to a novel antibody and an antibody fragment thereof that specifically bind to TIGIT and a composition comprising the antibody or the antibody fragment. In addition, the present invention relates to a nucleic acid encoding the antibody or the antibody fragment thereof, a host cell comprising the nucleic acid, and related use. Furthermore, the present invention relates to therapeutic and diagnostic use of the antibody and the antibody fragment.
    Type: Application
    Filed: July 25, 2019
    Publication date: February 11, 2021
    Inventors: Xinzhen SHI, Pan ZHANG, Junjian LIU